Maximizing the Clinical Benefit of Radiotherapy in Solitary Plasmacytoma: An International Multicenter Analysis
Open Access
- 12 March 2020
- Vol. 12 (3), 676
- https://doi.org/10.3390/cancers12030676
Abstract
Objective: Although local definitive radiotherapy (RT) is considered the standard of care for solitary plasmacytoma (SP), the optimal RT parameters for SP patients have not been defined. The aim of this retrospective study is to analyze the effectiveness of various RT doses, volumes, and techniques, as well as to define the relevant prognostic factors in SP. Methods: Between 2000 and 2019, 84 patients, including 54 with solitary bone plasmacytoma (SBP) and 30 with extramedullary plasmacytoma (EMP), underwent RT at six institutions. Results: The overall RT median dose was 42 Gy (range, 36.0–59.4). The median follow-up period was 46 months. Overall, the local control (LC) rate was 96%, while the complete remission (CR) rate was 46%. The 5-year local relapse-free survival (LRFS), multiple myeloma-free survival (MMFS), progression-free survival (PFS), and overall survival (OS) rates were 89%, 71%, 55%, and 93%, respectively. Using an RT dose above 40 Gy was associated with a higher complete remission (CR) rate and a lower rate of local relapse. Modern irradiation techniques were associated with a trend toward a higher LC rate (98% vs. 87% for conventional, p = 0.09) and a significantly lower local relapse rate (6% vs. 25% for conventional, p = 0.04). However, RT dose escalation and technique did not lead to a significant effect on MMFS, PFS, and OS. Univariate analyses identified several patient characteristics as potentially relevant prognostic factors. In SBP patients, systemic therapy administration was associated significantly with MMFS and PFS rates. Conclusion: Using an RT dose >40 Gy and modern RT techniques may improve the local control and reduce the rate of relapse, without a significant impact on survival rates. The addition of systemic therapies may improve the MMFS and PFS rates of SBP patients.This publication has 34 references indexed in Scilit:
- New insights in the treatment of patients with solitary bone plasmacytomaLeukemia & Lymphoma, 2019
- Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology GroupInternational Journal of Radiation Oncology*Biology*Physics, 2018
- Treatment approaches and outcomes in plasmacytomas: analysis using a national datasetLeukemia, 2018
- 18F–FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myelomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patientsChinese Journal of Cancer Research, 2017
- Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysisBlood, 2014
- Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple MyelomaThe New England Journal of Medicine, 2013
- Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trialRadiotherapy and Oncology, 2011
- Solitary plasmacytomasCancer, 2011
- Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network studyBMC Cancer, 2006